doi: 10.6004/jnccn.2017.0175.
Myeloid Growth Factors, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology
- PMID: 29223990
- DOI: 10.6004/jnccn.2017.0175
Item in Clipboard
Myeloid Growth Factors, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology
J Natl Compr Canc Netw.
2017 Dec.
Abstract
Myeloid growth factors (MGFs) are given as supportive care to patients receiving myelosuppressive chemotherapy to reduce the incidence of neutropenia. This selection from the NCCN Guidelines for MGFs focuses on the evaluation of regimen- and patient-specific risk factors for the development of febrile neutropenia (FN), the prophylactic use of MGFs for the prevention of chemotherapy-induced FN, and assessing the risks and benefits of MGF use in clinical practice.
Copyright © 2017 by the National Comprehensive Cancer Network.
Similar articles
-
Controversies Regarding Use of Myeloid Growth Factors in Leukemia.J Natl Compr Canc Netw. 2017 Dec;15(12):1551-1557. doi: 10.6004/jnccn.2017.7044. J Natl Compr Canc Netw. 2017. PMID: 29223992 Review.
-
A comparison of international guidelines for the prevention of chemotherapy-induced neutropenia.Curr Opin Hematol. 2011 Jan;18(1):1-10. doi: 10.1097/MOH.0b013e328340dc51. Curr Opin Hematol. 2011. PMID: 21042215 Review.
-
A Patient Risk Model of Chemotherapy-Induced Febrile Neutropenia: Lessons Learned From the ANC Study Group.J Natl Compr Canc Netw. 2017 Dec;15(12):1543-1550. doi: 10.6004/jnccn.2017.7038. J Natl Compr Canc Netw. 2017. PMID: 29223991 Review.
-
Febrile neutropenia (FN) occurrence outside of clinical trials: occurrence and predictive factors in adult patients treated with chemotherapy and an expected moderate FN risk. Rationale and design of a real-world prospective, observational, multinational study.BMC Cancer. 2018 Sep 24;18(1):917. doi: 10.1186/s12885-018-4838-z. BMC Cancer. 2018. PMID: 30249215 Free PMC article.
-
Myeloid growth factors.J Natl Compr Canc Netw. 2013 Oct 1;11(10):1266-90. doi: 10.6004/jnccn.2013.0148. J Natl Compr Canc Netw. 2013. PMID: 24142827
Cited by
-
The characteristics and clinical course of patients with melioidosis and cancer.PLoS Negl Trop Dis. 2024 Oct 25;18(10):e0012631. doi: 10.1371/journal.pntd.0012631. eCollection 2024 Oct. PLoS Negl Trop Dis. 2024. PMID: 39453944 Free PMC article.
-
A randomized, multicenter phase III Study of once-per-cycle administration of efbemalenograstim alfa (F-627), a novel long-acting rhG-CSF, for prophylaxis of chemotherapy-induced neutropenia in patients with breast cancer.BMC Cancer. 2024 Sep 13;24(1):1143. doi: 10.1186/s12885-024-12892-5. BMC Cancer. 2024. PMID: 39272058 Free PMC article. Clinical Trial.
-
The long-term impact of an antimicrobial stewardship program in febrile neutropenia: an 8 years follow up.Eur J Clin Microbiol Infect Dis. 2024 Nov;43(11):2171-2176. doi: 10.1007/s10096-024-04939-z. Epub 2024 Sep 12. Eur J Clin Microbiol Infect Dis. 2024. PMID: 39264372
-
Leveraging G-CSF prescribing in the outpatient setting: considerations beyond clinical factors-a questionnaire study.Support Care Cancer. 2024 May 14;32(6):347. doi: 10.1007/s00520-024-08524-0. Support Care Cancer. 2024. PMID: 38743147
-
The effect of leptin gene polymorphisms (LEP rs7799039 and LEPR rs1137101) on febrile neutropenia.Heliyon. 2024 Mar 28;10(7):e28788. doi: 10.1016/j.heliyon.2024.e28788. eCollection 2024 Apr 15. Heliyon. 2024. PMID: 38586343 Free PMC article.
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous
